Real-World Safety and Clinical Response of Janus Kinase Inhibitor Upadacitinib in the Treatment of Hidradenitis Suppurativa: A Retrospective Cohort Study

Published: 25 July 2022| Version 1 | DOI: 10.17632/fjv74v2w65.1
Contributor:
John Frew

Description

Real-World Safety and Clinical Response of Janus Kinase Inhibitor Upadacitinib in the Treatment of Hidradenitis Suppurativa: A Retrospective Cohort Study - JAAD 2022

Files

Categories

Dermatology, Hidradenitis Suppurativa, Janus Kinase

License